A prospective cohort study on the trajectory of health-related quality of life in adult childhood cancer survivors attending a follow-up care program

Abstract

Follow-up care in adult childhood cancer survivors (ACCS) aims to screen for, prevent, and treat potential late effects. The trajectory of ACCS’ health-related quality of life (HRQoL) attending follow-up care is unclear. We investigated changes in HRQoL of ACCS attending a follow-up care program. The primary outcome was the minimal clinically important decrease (MCID) in HRQoL of ≥ 5 points in the mental (MCS) and/or physical component score (PCS) of the 36-item Short Form (SF-36) between baseline and follow-up (3-months after the first visit). We compared baseline characteristics, psychological factors, satisfaction, and distress (measured using the Brief Symptom Inventory). In 47 ACCS (100%), no significant change in the overall median MCS and PCS was observed. In 14 ACCS (29.8%) a MCID in HRQoL was observed. Compared to ACCS without a MCID, they reported lower PCS (median 45.2 [31.7; 51.4] vs. 55.6 [46.1; 57.6], p = 0.007), a higher proportion of low physical health (PCS < 48; 71.4% vs. 27.3%, p = 0.009) and distress (50% vs. 18.8%, p = 0.030) at baseline. Satisfaction was high (94.9%). One in three ACCS experienced a clinically important decrease in HRQoL after follow-up care, with higher rates in those with lower physical health and higher psychological distress at baseline.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-025-92820-0.

Introduction

Over the past 30 years, childhood cancer survival rates have improved drastically and exceeded 81% in most European countries for children diagnosed between 2010 and 2014¹. In Switzerland, survival rate exceeded 85% for children diagnosed between 2014 and 2018². Although overall survival is high, most adult childhood cancer survivors (ACCS) experienced late effects due to the cancer or its treatments^3–5. Chronic health conditions occurred earlier and more frequently in ACCS compared to peers of the same age groups^3–5. Psychological distress, fear of cancer recurrence, anxiety, and depressive symptoms were present in ACCS^4,6–8. They resulted in a high burden of disease during adulthood and may affect health-related quality of life (HRQoL)^4,9. Long-term follow-up care aims to reduce the burden of late effects through early detection, treatment, and prevention^3,10–13. Additionally, ACCS may need psychological support and lifestyle counselling^3,6,9.

In ACCS who attended structured and tailored follow-up care more late effects were detected compared to ACCS who did not attend follow-up care^12,14 or ACCS with follow-up care provided by primary care physicians^12,15. The detected follow-up effects ranged from medical conditions such as osteoporosis, endocrinopathy and pulmonary disfunction to secondary malignancies and psychosocial late effect such as higher distress levels^12,15. Follow-up care increased the awareness for potential late effects¹⁶ and reduced the number of emergency department visits and hospitalizations¹⁷. Thus, international guidelines recommend regular follow-up care that is personalized based on the initial cancer and its treatments^18,19. Although follow-up care is intended to reassure ACCS and improve outcomes, some ACCS reported that follow-up care visits were associated with stress, anxiety, or fear of detecting new health problems^20–22. Some ACCS discontinued follow-up care because they “wanted to draw a line under it”²³. In a Swiss study, psychological distress persisted or newly occurred in 36% of participants after the follow-up care visit²⁴. Psychological factors were associated with a decreased HRQoL in ACCS^9,25,26. However, there is little research on the trajectory of quality of life, psychological variables, fear, and satisfaction in ACCS who attend a follow-up care program¹².

Therefore, we aimed to (1) analyze the trajectory of HRQoL in ACCS from before to three months after the first visit in a follow-up care program, and to (2) describe and compare the baseline characteristics of ACCS with a clinically important decrease in HRQoL and ACCS without a MCID in HRQoL three months after the initial visit. Finally (3), we analyzed and report findings from individual feedback to follow-up care visits that may help to improve individualized follow-up care. We hypothesized that ACCS with a MCID in HRQoL have more late effects, experience more psychological distress, and report a lower HRQoL at baseline. We further hypothesized that ACCS with a MCID in HRQoL report lower satisfaction and increased fears and worries since the follow-up care visit.

Methods

Study design, eligibility criteria, and setting

This is a prospective multicenter cohort study of ACCS attending a follow-up care program at two Swiss hospitals (University Hospital Bern, Bern and Kantonsspital Baselland, Liestal). The study is reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement²⁷. The cohort study has been approved by the local ethical committees of North-Eastern Switzerland and Bern (EKNZ, Basec ID 2017 − 00109), and all participants provided informed consent. The study was performed in accordance with the regulations and guidelines of the ethical committee. The prospective cohort trial protocol was designed as a quality improvement project and not registered.

ACCS (≥ 18 years at consent, < 20 years at cancer diagnosis, see prior publication for details²⁸) attending their first visit in a follow-up care program were asked to participate in a cohort study. For the current study, we included all ACCS who consented to the cohort study, attended the first follow-up care visit between February 2017 and May 2021, and completed the 36-item Short Form survey, version 2 (SF-36), at baseline and at three months follow-up. We excluded ACCS with multiple consultations between baseline and follow-up data collection and ACCS with missing baseline and/or follow-up data of the SF-36 (Supplementary Fig. 1).

The follow-up care visit was planned within an interdisciplinary team led by a physician specialized in general internal medicine and a pediatric oncologist. To ensure evidence-based follow-up care, the Passport for Care^® application was used to personalize the Children’s Oncology Long-Term Follow-Up guidelines²⁹.

Procedures

ACCS completed a consent form and baseline questionnaires (SF-36, Brief Symptom Inventory (BSI), demographic and cancer history-related questions) before their first visit in the follow-up care program. ACCS returned the questionnaires by postal mail or e-mail to the follow-up care team. Based on the questionnaires, the follow-up care visit was tailored to meet individual needs. During the follow-up care visit, physicians and specialized nurses collected medical history and physical findings. Further, laboratory tests and other examinations (e.g., echocardiogram) were performed based on the recommendations from the Children’s Oncology Long-Term Follow-Up guidelines and the patient’s history and findings. Approximately, three months after the follow-up care visit, ACCS received a follow-up questionnaire (SF-36, questions about worries, fear, satisfaction, and open-ended feedback questions; no BSI data was obtained three months after the visit) by e-mail or postal mail. Two reminders were sent to non-responders (the first after one month, the second after two months). A research fellow, not involved in the follow-up care visit, entered questionnaires, clinical information from medical reports, and test results into a database. We chose a 3-month follow-up to allow ACCS time to process the information provided during the clinical visit and still be able to provide valuable feedback regarding the clinical visit and their respective needs. The SF-36 items address domains in the preceding four weeks³⁰ and thus, the chosen period represents an adequate distance between the clinical visit and the follow-up assessment.

Primary outcome

The primary outcome was the decrease in HRQoL between baseline and follow-up measured using the reliable and validated SF-36^30–33. The SF-36 assesses eight subscales (physical functioning, physical role function, bodily pain, general health, vitality, social functioning, emotional role function, and mental health) and can be summarized in two summary scales (physical component summary (PCS), mental component summary (MCS). For each subscale, a score is calculated (higher scores indicate better HRQoL; range 0-100) and standardized to the Swiss general population normative data (mean = 50, SD = 10 in the Swiss general population)^30,34. We calculated the change between baseline and follow-up in the MCS and PCS scores. A decrease of ≥ 5 points in MCS and/or PCS score from baseline to follow-up was considered a minimal clinically important decrease (MCID) in HRQoL. We compared ACCS with a MCID in HRQoL to ACCS with stable or increased HRQoL. Low physical HRQoL was defined as PCS T-score < 48 points and low mental HRQoL as MCS T-score < 35 points. We used these cut-off values because they have been derived and used in the Swiss Childhood Cancer Survivor Study³¹.

Additional outcomes

Additional outcomes included satisfaction, worries, and fear. Questions validated in an oncological population³⁵ assessed satisfaction: “There were aspects of my overall visit with the doctor that I was not very satisfied with” and potential for improvement: “There were some things about my visit with the doctor that could have been better”. Answers on a four-point Likert scale (absolutely agree, agree, disagree, absolutely disagree) were dichotomized into “no unsatisfactory aspects”/”no potential for improvement” (absolutely disagree, disagree) and “some unsatisfactory aspects”/”some potential for improvement” (absolutely agree, agree). ACCS were asked to provide feedback to three open questions: “Could certain things have gone better during the consultation?”, “Have there been other topics that were discussed during the consultation?”, and “Open feedback”.

We asked about worries and fears using two questions: “Since the visit, I have been more worried about my health status than before” (worries) and “Since the visit, my fears are greater than before” (fear). Responses on a four-point Likert scale (absolutely agree, agree, disagree, absolutely disagree) were dichotomized into “yes” (absolutely agree, agree) or “no” (disagree, absolutely disagree).

Covariates

Baseline factors included socio-demographic characteristics (age, sex, Swiss / Non-Swiss, education, employment), cancer (based on the prevalence^2,36 grouped into CNS tumor, leukemia, lymphoma, sarcoma, and others), age at diagnosis, year of the diagnosis, cancer related treatment (surgery, chemotherapy, and/or radiotherapy) and completion of the treatment, relapse of cancer, health conditions (chronic diseases and chronic medication use), and psychological variables.

Late effects were secondary malignancies, diseases per organ systems with the overall number of affected organ systems based on health records and chronic medication use as a proxy for cardiovascular disease (i.e., diuretics, nitrate, anticoagulant, antihypertensive, and statin use), diabetes (i.e., oral antidiabetics or insulin use), and endocrine disease (i.e., hydrocortisone, mineralocorticoid, desmopressin, and thyroid, sexual or growth hormones use).

Psychological baseline variables were based on the reliable and validated Brief Symptom Inventory (BSI)^6,37,38. The BSI consists of 53 items and assesses nine subscales: somatization, obsessive-compulsive tendencies, interpersonal sensitivity, depression, anxiety, aggression, phobic anxiety, paranoid ideation, and psychotic tendencies. Each item expresses a statement on how much ACCS suffered from a problem described during the previous 7 days (scores range from 1 = not at all to 5 = very much). The Global Severity Index (GSI) measures general psychological distress, as it portrays the average of all subscale values (range 1–5). The values of the GSI and the subscales were converted to T-scores (higher scores indicating higher distress) using German normative data (mean = 50, SD = 10 in the German general population)³⁷. Psychological distress was defined as GSI T-score ≥ 63 and/or a T-score ≥ 63 in at least two subscales^37,38.

Statistical analysis

Descriptive statistics were used to characterize the study population. For continuous variables, we reported the median and interquartile range (IQR). For categorical variables, we reported proportions and frequencies. We compared baseline characteristics between groups using Wilcoxon rank-sum tests for continuous variables, and chi-square or Fisher’s exact tests for categorical variables, as appropriate³⁹. We compared MCS, PCS and SF-36 subscales at baseline and follow-up using the sign-rank test⁴⁰.

We analyzed free-text feedback according to qualitative content analysis by Mayring⁴¹, using QCAmap, an open access program⁴². Specific aspects of the free-text data were categorized into three main groups (positive feedback, negative feedback, and feedback without emotional connotation). The intra-coder agreement was assessed with a time difference of 60 days.

Missing data was reported in the tables. Missing values were handled according to the respective manuals for the scales: SF-36 User’s Manual³⁰ and the BSI manual³⁷. No further imputation was done. All statistical analyses were performed using STATA 16.0 IC software. Graphics were created using STATA 18.0 IC software (STATA Corp., College Station, TX, USA). All p-values < 0.05 were considered statistically significant. Because all analyses were exploratory, we refrained from adjusting for multiple testing.

Results

Study population and descriptive data

Out of 102 ACCS (100%) who provided informed consent for the cohort study, 47 ACCS (46.1%) met the eligibility criteria for this study and were analyzed (Supplementary Fig. 1). The median age was 25.7 years [IQR 21.3; 38.9], 66.0% were female, and 79.1% were employed (Table 1). The median age at cancer diagnosis was 9.0 years [4.2; 13.2] with a median time since diagnosis of 20.0 years [12.0; 29.0]. The main cancer groups were leukemia (n = 15, 31.9%), lymphoma (n = 11, 23.4%), CNS tumor (n = 9, 19.2%), sarcoma (n = 6, 12.8%), and others (n = 7, 14.8%; Langerhans cell histiocytosis n = 1, neuroblastoma n = 3, retinoblastoma n = 1, germ cell tumor n = 1, and renal tumor n = 1). ACCS reported a median of 5 [4; 8] late effects and the median time between the follow-up care visit and follow-up questionnaire was 132 days [100; 281].

Table 1.

Baseline characteristics for the total study population and for the ACCS with and without a MCID in HRQoL.

Characteristics	Total	No clinically important decrease in HRQoL	Clinically important decrease in HRQoL	p-value
	N (%) or median [IQR]
Total	47 (100)	33 (70.2)	14 (29.8)
Socio-demographic characteristics
Age, years	25.7 [21.3, 38.9]	24.8 [21.2, 36.3]	33.5 [23.5, 41.9]	0.077
Female sex	31 (66.0)	20 (60.6)	11 (78.6)	0.331
Migration background1	5 (10.9)	5 (15.1)	0 (0.0)	0.301
Education2				0.800
Compulsory schooling	10 (22.2)	8 (25.8)	2 (14.3)
Vocational training/apprenticeship	16 (35.6)	11 (35.5)	5 (35.7)
Highschool	7 (15.6)	4 (12.9)	3 (21.4)
Tertiary Education	12 (26.7)	8 (25.8)	4 (28.6)
Employment3				0.304
Current employment	35 (79.6)	22 (73.3)	13 (92.9)
Continuing education	5 (11.4)	5 (16.7)	0 (0.0)
Unemployed	4 (9.1)	3 (10.0)	1 (7.1)
Cancer history related information
Age at diagnosis, years	9.0 [4.2, 13.2]	8.9 [4.2, 12.4]	11.7 [4.2, 14.7]	0.577
Diagnosis				0.426
CNS Tumor	9 (19.2)	7 (21.2)	2 (14.3)
Leukemia	15 (31.9)	11 (33.3)	4 (28.6)
Lymphoma	11 (23.4)	5 (15.2)	6 (42.9)
Sarcoma	6 (12.8)	5 (15.2)	1 (7.1)
Others	6 (12.8)	5 (15.2)	1 (7.1)
Years since diagnosis	20 [12, 29]	18 [12, 27]	27 [15, 31]	0.209
Year of the diagnosis				0.393
Before 1980	13 (6.4)	1 (3.0)	2 (14.3)
1980–1989	9 (19.2)	7 (21.2)	2 (14.3)
1990–1999	13 (27.7)	8 (24.2)	5 (35.7)
2000–2009	13 (27.7)	11 (33.3)	2 (14.3)
After 2009	9 (19.2)	6 (18.2)	3 (21.4)
Treatment
Surgery	35 (74.5)	24 (72.7)	11 (78.6)	1.000
Chemotherapy	45 (95.7)	32 (97.0)	13 (92.9)	0.512
Radiotherapy	28 (59.6)	20 (60.6)	8 (57.1)	0.825
Years since end of treatment	18.5 [10, 27]	15.5 [9.5, 26]	25 [15, 28]	0.148
Relapse	4 (9.1)	3 (10.0)	1 (7.2)	1.000
Late effects
Secondary malignancies	11 (23.4)	7 (21.2)	4 (28.6)	0.710
Number of late effects	5 [4, 8]	5 [3, 8]	6 [4, 8]	0.453
Organ system specific late effects
Cardiovascular	16 (34.0)	14 (42.2)	2 (14.3)	0.094
Endocrinological	29 (61.7)	22 (66.7)	7 (50.0)	0.282
Musculoskeletal	29 (61.7)	20 (60.6)	9 (64.3)	0.812
Neurological	22 (46.8)	14 (42.2)	8 (57.1)	0.355
Pulmonal comorbidities	18 (38.3)	15 (45.5)	3 (21.4)	0.191
Renal comorbidities	9 (19.2)	8 (24.2)	1 (7.1)	0.244
Chronic pain	10 (21.3)	7 (21.2)	3 (21.4)	1.000
Total number of chronic medications4	3 [1, 4]	2.5 [1, 3.5]	3 [1, 5]	0.346
Cardiovascular active medication	2 (4.3)	2 (6.1)	2 (0.0)	1.000
Antidiabetics	1 (2.1)	1 (3.0)	0 (0.0)	1.000
Endocrinological active medication	18 (38.3)	13 (39.4)	5 (35.7)	1.000
HRQoL, SF-36 baseline
MCS (T-score)	52.5 [43.9, 56.4]	53.3 [43.9, 56.6]	50.4 [45.3, 54.7]	0.340
PCS (T-score)	51.4 [42.5, 56.9]	55.6 [46.1, 57.6]	45.2 [31.7, 51.4]	0.007
SF-36 subscales (T-score)
Physical functioning	52.3 [43.5, 55.2]	52.3 [49.3, 55.2]	46.4 [40.5, 52.3]	0.038
Physical role function	56.5 [41.4, 56.5]	56.6 [47.5, 56.6]	49.0 [38.4, 56.6]	0.344
Bodily pain	49.8 [41.3, 59.8]	59.8 [49.8, 59.8]	41.3 [33.3, 41.3]	< 0.001
General health	53.6 [36.3, 59.3]	53.7 [42.1, 59.4]	43.0 [30.6, 56.6]	0.155
Vitality	49.5 [38.6, 56.8]	49.6 [42.3, 56.8]	45.9 [31.4, 49.6]	0.059
Social role functioning	57.0 [38.2, 57.0]	57.1 [44.6, 57.1]	44.6 [32.1, 57.1]	0.038
Emotional role function	56.3 [47.6, 56.3]	56.4 [47.8, 56.4]	56.4 [34.8, 56.4]	0.770
Mental health	53.0 [46.8. 56.1]	53.1 [50.0, 56.2]	53.1 [43.8 53.1]	0.139
Low mental healtha	4 (8.5)	1 (3.0)	3 (21.4)	0.073
Low physical healthb	19 (40.4)	9 (27.3)	10 (71.4)	0.009
Psychological factors
BSI baseline5
GSI (T-Score)	48 [35, 63]	44 [35, 54]	56 [52, 65]	0.008
BSI subscales (T-Score)
Somatization	49 [41, 56]	41 [40, 54]	62.5 [56, 66]	0.001
Obsessive-compulsive tendencies	51 [42, 59]	47 [42, 56.5]	60.5 [51, 68]	0.012
Interpersonal sensitivity	50 [41, 56]	46 [39.5, 54]	52 [46, 65]	0.115
Depression	46 [40, 56]	43 [40, 54]	55 [40, 68]	0.069
Anxiety	50 [40, 58]	46.5 [40, 55]	56 [45, 61]	0.061
Hostility	50 [40, 61]	46 [40, 59.5]	55.5 [46, 61]	0.223
Phobic anxiety	45 [44, 56]	45 [44, 56]	49.5 [44, 60]	0.765
Paranoid ideation	41 [40, 55]	41 [40, 54.5]	45 [40, 58]	0.788
Psychoticism	44 [43, 54]	44 [43, 54]	44 [43, 59]	0.592
Psychological distressc	13 (28.3)	6 (18.8)	7 (50.0)	0.030

MCID, Minimally clinically important decrease; HRQoL, Health Related Quality of Life; CNS, Central nervous system; MCS, Mental Component Score; PCS, Physical Component Score; SF-36, 36-item Short Form survey; BSI, Brief Symptom Inventory; GSI, Global Severity Index.

^aDefined as MCS T-score < 35.

^bDefined as PCS T-score < 48.

^cDefined as T-score of the GSI ≥ 63 and/or the T-score of at least 2 subscales ≥ 63.

Missing data, due to incomplete questionnaires.

¹Migration background: 1 (2.1%) missing value: 1 (2.9%) in ACCS with MCID in HRQoL.

²Education: 2 (4.3%) missing values: 2 (6.1%) in ACCS with no MCID in HRQoL.

³Employment: 3 (6.4%) missing values: 3 (9.1%) in ACCS with no MCID in HRQoL.

⁴Total number of current medication: 1 (2.1%) missing value: 1 (2.9%) in ACCS with no MCID in HRQoL.

⁵BSI: 1 (2.1%) missing value: 1 (3.0%) in ACCS with no MCID in HRQoL.

Significant values are in (bold).

The median MCS score at baseline was 52.5 [43.9; 56.4] and the median PCS score 51.4 [42.5; 56.9] with 8.5% reporting low mental HRQoL and 40.4% low physical HRQoL (Table 1). Baseline psychological distress was present in 28.3% of the overall population with a median GSI T-score of 48.5 [37; 63]. No difference between included and excluded ACCS in the baseline characteristics was observed except for SF-36 subscales for general health (median included 53.7 vs. excluded 46.8, p-value = 0.048) and emotional role functioning (56.4 vs. 52.1, p-value = 0.037) (Supplementary Table 1).

Primary outcome

In the overall group, the median MCS score at follow-up was 51.2 [42.3; 56.8] and the median PCS score was 50.4 [39.7; 57.7] (see Table 2 for SF-36 subscales). The changes between baseline and follow-up in the MCS was − 0.3 (IQR [− 3.4; 2.4], p = 0.882) and in the PCS − 0.2 (IQR [− 3.5; 3.0], p = 0.592; Supplementary Table 2). A total of 14 ACCS (29.8%) reported a MCID in HRQoL between baseline and follow-up (MCS n = 9 (19.2%), PCS n = 8 (17.0%), and in both n = 3 (6.4%)). In this group, the median MCS change was − 7.3 [− 10.7; − 0.5] and the median PCS change − 6.4 [− 11.4; 0.6] (Table 2). Compared to ACCS without a MCID in HRQoL, ACCS with a MCID in HRQoL reported particularly strong decreases in the SF-36 subscales for physical role functioning (median change − 10.6 [− 18.2; − 3.0] vs. 0 [0; 0], p < 0.001), general health (− 7.2 [− 11.5; 0] vs. 0 [− 4.6; 5.5], p = 0.004), social role functioning (− 6.2 [− 12.5; 0] vs. 0 [0; 0], p = 0.001), and emotional role functioning (− 6.5 [− 21.7; 0] vs. 0 [0; 4.3], p = 0.001) (Table 2).

Table 2.

HRQoL at follow-up and its change between baseline and follow-up.

	Follow-up			p value	Change between baseline and follow-up			p value
	Total	No clinically important decrease in HRQoL	Clinically important decrease in HRQoL		Total	No clinically important decrease in HRQoL	Clinically important decrease in HRQoL
	Median [IQR]				Median [IQR]
MCS (T-score)	51.2 [42.3, 56.8]	54.5 [49.5, 57.0]	43.1 [31.7, 45.9]	0.002	− 0.3 [− 3.4, 2.4]	1.1 [− 1.2, 3.2]	− 6.4 [− 11.4, 0.6]	0.004
PCS (T-score)	50.4 [39.7, 57.7]	54.1 [50.0, 58.0]	34.1 [28.5, 44.1]	< 0.001	− 0.16 [− 3.5, 3.0]	0.4 [− 0.7, 3.2]	− 7.3 [− 10.7, − 0.5]	0.002
SF-36 subscales (T-score)
Physical functioning	52.3 [46.4, 55.2]	55.2 [49.3, 55.2]	43.4 [25.8, 52.3]	0.002	0 [− 2.9, 2.9]	0 [0, 2.9]	− 4.4 [− 5.9, 0]	0.001
Physical role function	50.5 [38.4, 56.6]	56.6 [44.5, 56.6]	38.4 [32.3, 41.4]	< 0.001	0 [-3.0, 0]	0 [0, 0]	− 10.6 [− 18.2, − 3.0]	< 0.001
Bodily pain	59.8 [33.3, 59.8]	59.8 [59.8, 59.8]	33.3 [26.0, 41.3]	< 0.001	0 [0, 3.8]	0 [0, 7.3]	0 [− 8.1, 0]	0.015
General health	47.9 [32.3, 59.3]	50.8 [42.1, 59.4]	31.5 [24.8, 47.9]	0.001	0 [− 8.7, 1.9]	0 [− 4.6, 5.5]	− 7.2 [− 11.5, 0]	0.004
Vitality	49.6 [35.1, 56.8]	53.2 [45.9, 56.8]	38.7 [27.8, 45.9]	0.001	0 [− 3.6, 3.6]	2.4 [0, 3.6]	− 3.6 [− 3.6, 0]	0.008
Social role functioning	57.1 [38.3, 57.1]	57.1 [57.1, 57.1]	35.2 [25.9, 50.1]	< 0.001	0 [0, 0]	0 [0, 0]	− 6.2 [− 12.5, 0]	0.001
Emotional role function	56.4 [39.1, 56.4]	56.4 [52.1, 56.4]	36.9 [26.1, 52.1]	< 0.001	0 [− 4.3, 0]	0 [0, 4.3]	− 6.5 [− 21.7, 0]	0.001
Mental health	53.1 [43.8, 56.2]	53.1 [50.0, 56.2]	48.4 [38.4, 53.1]	0.006	0 [− 3.1, 3.1]	0 [− 3.1, 3.1]	− 1.6 [− 9.3, 3.1]	0.301

HRQoL, Health Related Quality of Life; MCS, Mental Component Score; PCS, Physical Component Score; SF-36, 36-item Short Form survey, version 2.

Significant values are in (bold).

Comparison of baseline characteristics in ACCS with and without MCID in HRQoL

Baseline socio-demographic and cancer-related characteristics were comparable in the two groups (Table 1). Whereas the MCS at baseline was comparable in both groups (Fig. 1a), ACCS with a MCID in HRQoL reported a lower physical HRQoL at baseline (PCS median 45.2 [31.7; 51.4] vs. 55.6 [46.1; 57.6], p = 0.007, Fig. 1b) and a higher proportion of low physical health (PCS < 48) (71.4% vs. 27.3%, p = 0.009). Significant differences in the SF-36 subscales at baseline were found in physical functioning (46.4 [40.5; 52.3] vs. 52.3 [49.3; 55.2], p = 0.037), bodily pain (41.3 [33.3; 41.3] vs. 59.8 [49.8; 59.8], p < 0.001) and social role functioning (44.6 [32.1; 57.1] vs. 57.1 [44.6; 57.1, p = 0.038) (Table 1).

Fig. 1.

(a) Baseline mental HRQoL (MCS T-score) for the overall study population (n = 47), ACCS with a MCID in HRQoL (n = 14), and ACCS without a MCID in HRQoL (n = 33). MCID, Minimally clinically important decrease; HRQoL, Health Related Quality of Life; MCS, Mental Component Score; ACCS, Adult Childhood Cancer Survivors. Higher MCS values indicate better mental HRQoL. p = 0.340, Wilcoxon rank-sum test. (b) Baseline physical HRQoL (PCS T-score) for the overall study population (n = 47), ACCS with a MCID in HRQoL (n = 14), and ACCS without a MCID in HRQoL (n = 33), p = 0.007. MCID, Minimally clinically important decrease; HRQoL, Health Related Quality of Life; PCS, Physical Component Score; ACCS, Adult Childhood Cancer Survivors. Higher PCS values indicate better physical HRQoL. p = 0.007, Wilcoxon rank-sum test.

Psychological distress at baseline was present in a higher proportion of ACCS with a MCID in HRQoL (50% vs. 18.8%, p = 0.030; higher median GSI T-score (56 [52; 65] vs. 44 [35; 54], p = 0.008) compared to ACCS who did not experience a MCID in HRQoL (Table 1, Supplementary Fig. 2).

Additional outcomes

At follow-up, 94.9% of ACCS reported no aspects they were not satisfied with during the follow-up care visit and most ACCS (85.4%) reported no potential for improvement for the follow-up care visit. There was no difference between ACCS with and without a MCID in HRQoL. There was a trend, albeit not significant, towards more worries (53.9% vs. 21.7%, p = 0.061) and fear (38.5% vs. 16.0%, p = 0.229) in ACCS with a MCID in HRQoL compared to ACCS without a MCID (Supplementary Table 3).

Qualitative responses

In total, we analyzed 44 free text answers written by 29 ACCS (19 answers by ACCS with a MCID in HRQoL, 21 answers by ACCS without a MCID in HRQoL) with 49 positive and 25 negative aspects. Supplementary Table 4 provides a summary of the reported aspects. Strong emotional responses included “With the new knowledge […] I realize that the unconscious pressure to be “normal”, healthy, like everyone else, has become much smaller.” and “For me, the annual examinations are a horror, because I get very scared.” Further examples are provided in Supplementary Table 5. ACCS with a MCID in HRQoL provided more often free text answers and mentioned more positive aspects (gratitude, holistic view, and relief).

Discussion

This study analyzed the trajectory of HRQoL of 47 ACCS attending their first visit in a follow-up care program. Overall, mental and physical HRQoL showed no significant difference from before to three months after the visit. However, one-third of ACCS reported a MCID in HRQoL three months after the follow-up care visit. ACCS with a clinically important decrease in HRQoL, reported at baseline lower physical health scores, a higher proportion of low physical health and psychological distress compared to ACCS without a clinically important decrease in HRQoL. Despite their decrease in HRQoL, most ACCS were satisfied with the follow-up care visit. ACCS reported a wide variation in strong emotions related to the follow-up care visit which may be addressed by clinicians.

The underlying reasons for the varying trajectories in HRQoL and particularly the decrease in HRQoL among a third of the study population, remain unknown and warrant further studies. According to a systematic review published in 2017, only little is known about the psychosocial impact of follow-up care in ACCS¹². Our study shows that one-third of ACCS attending the follow-up care program reported a clinically relevant decrease in HRQoL over the following three months. Whether this finding is a result of the follow-up care visit or occurs independently from the visit needs to be assessed in future studies. One may hypothesize that follow-up care visits might, although well intended, be associated with distress and anxiety. Previous studies showed, that the discussion and findings during the follow-up care visits may contribute to psychological distress among attendees by increasing nervousness, generating stress, and provoking fears of cancer recurrence and new late effects^20–22,43. In adolescent childhood cancer survivors follow-up care visits were associated with a decrease in overall psychological distress²⁴. However, one-third of survivors reported persistent psychological distress, and some adolescents reported new distress after the follow-up care visit. ACCS in our study reported strong emotions due to the re-experiencing of cancer-related memories when entering medical institutions or the thoughts about late effects that will persist or may develop. However, preexisting psychological factors and lower physical health may indicate that these ACCS are at risk of a further decline in HRQoL.

Preexisting psychological distress may also persist in some cancer survivors after a follow-up care visit²⁴ and independently decrease HRQoL. In a U.S. childhood cancer survivor study, high psychological distress scores (measuring anxiety, depression, and somatization) were associated with lower HRQoL in all domains²⁶. Psychological distress seems to coexist with low HRQoL^25,44 and could independently lead to a further decrease in HRQoL. Compared to the Swiss population (high distress in 18.1%⁴⁵) and the Swiss Childhood Cancer Survivor Study (high distress in 14.4%⁶ and 13%⁸), a higher proportion of ACCS in our study reported high psychological distress (28.3%) at baseline, which may also explain some of the observed decrease in HRQoL. Whether ACCS with more severe late effects¹³ and psychological distress⁴⁶ are more likely to seek out follow-up care and therefore, are at risk for decreased HRQoL remains unknown. Thus, further studies should assess the causal pathways that result in these findings.

Although our study population was young (median age: 25.7 years), a median of five chronic late effects requiring medical care were reported. Childhood cancer survivors attending follow-up care programs were more likely to self-report late effects compared to survivors without follow-up care¹³. During follow-up care visits new late effects are frequently discovered^12,15. New or persisting medical late effects negatively influence HRQoL^31,47,48 and result in psychological distress⁶. In our study, we observed no difference in the number of late effects and chronic medication use between ACCS with and without a MCID in HRQoL. It is hypothesized that somatic late effects do not affect HRQoL per se but rather via high psychological distress^26,33. American ACCS with a higher burden of chronic health conditions at baseline reported a lower HRQoL later on during the St. Jude Lifetime Cohort Study⁴⁹. The timeframe of change, as well as any causal pathway, remains still unclear and warrants further research.

While both MCS and PCS assess HRQoL, they measure distinct aspects. Late effects and cancer experiences can influence both scales negatively, positively and not at all^31,44,47. In the Swiss Childhood Cancer Survivor Study, all health problems reduced HRQoL across all scales, but the PCS was more affected³¹. Whereas no difference between the MCS in ACCS compared to their siblings was observed in the U.S., ACCS reported lower PCS scores⁴⁷. Due to the small patient cohort, we were not able to compare differences between ACCS with a MCID in MCS to those with a MCID in the PCS. Future research in a larger cohort is warranted to explore the differences in health trajectories and baseline characteristics between these groups.

Only limited evidence is available on how to approach psychological and HRQoL related aspects during follow-up care. Studies suggest that identifying and addressing distress and aspects that affect quality of life may improve HRQoL over time^24,50. Adolescent childhood cancer survivors perceived greater benefits from distress screening when their identified issues were discussed, compared to when the screened issues remained undiscussed²⁴. One aspect observed in our study population showed that there may were unmet or unrealistic expectations. Although the follow-up care visit lasted a whole day in our setting, some answers indicate that expectations were not always met (missing answers, insufficient time, or a perceived lack of care after the follow-up care visit). Other studies also observed a need for more psychosocial support, information, and individualized content^20,23,51,52. An unfulfilled information need is associated with higher psychological distress and lower HRQoL in ACCS^52,53. Thus, providing information could mitigate distress following the follow-up care visit.

Overall, satisfaction with the follow-up care visit and the doctor encounter was high in our study and also in a study in pediatric cancer survivors⁵⁰. A recent study from Geneva showed similar results as most ACCS perceived a follow-up care visit reassuring and satisfactory²⁰.

Limitations

Although the study addresses an important topic, several limitations need to be discussed. First, the main limitation of our study is the small sample size, the short follow-up duration, and that we had no control group to compare ACCS with to those without follow-up care. The high proportion of baseline distress compared to previous studies suggest that a selected ACCS population with specific needs attended the follow-up care program. Thus, our findings may be limited to our program and not generalizable to other follow-up care settings and all ACCS. Second, a response rate of 46.1% indicates a substantial proportion of ACCS who did not or were not able to return a follow-up questionnaire. Although there were no relevant differences in the baseline characteristics between ACCS who completed the questionnaires and ACCS who did not, our findings may not be generalizable to all survivors attending the follow-up care program. Furthermore, our study was exploratory, and these findings warrant validation in other settings and with larger patient samples. Thus, we cannot infer causality. Finally, given the small patient cohort, we were not able to assess differences between ACCS with a MCID in the MCS compared to those with a MCID in the PCS. The MCS and the PCS are different health related quality of life outcomes. Thus, future studies need to assess differences between the two outcomes, the causal pathways on how HRQoL is influenced and what appropriate and effective preventive interventions are. Finally, ACCS completed baseline and follow-up questionnaires at different times before and after the follow-up care visit. Thus, recall bias and other factors may have influenced the results.

Implication for clinical practice

Low physical HRQoL and the presence of psychological distress at baseline may identify ACCS who are vulnerable to a MCID in HRQoL following the first clinical follow-up care visit in a follow-up care program. Clinicians need to be aware of psychological aspects that are associated with the attendance at follow-up care visits and eventually may influence HRQoL. The presence of low physical HRQoL and psychological distress may be modifiable factors that have been shown in other studies to influence HRQoL. In ACCS experiencing increased distress, inquiring about the reasons for their distress and discussing HRQoL problems may improve HRQoL trajectories and subjective well-being^24,50.

Implication for research

Future studies should assess the causal pathways between distress, late effects and HRQoL in ACCS. Our findings need to be confirmed in a larger survivor population. A decrease in HRQoL over time has been observed in the American St. Jude Lifetime Cohort Study⁴⁹ in ACCS with more somatic late effects. Thus, studies with longer follow-up duration should assess HRQoL trajectories in ACCS. Finally, future studies should focus on developing and implementing interventions aimed at reducing the potential negative impact of follow-up care visits on HRQoL in ACCS and subsequently evaluate their efficacy.

Conclusion

In ACCS attending a follow-up care visit, one in three ACCS reported a clinically relevant decrease in HRQoL from before to three months after the visit. ACCS with a clinically important decrease in HRQoL reported lower physical health and higher psychological distress at baseline. These ACCS may profit from being flagged for extra care. The causal pathway between a decrease in HRQoL after a follow-up care visit and low physical health and high psychological distress at baseline, however, is still unknown and warrants further investigation.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by L.V, K.R, E.M.T, C.B, C.E.K and M.M.W. The analysis was done by C.E.K., C.B., and K.R. All authors interpreted the results and contributed to the interpretation. The first draft of the manuscript was written by C.E.K and M.M.W. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the science funds of the University Institute of Internal Medicine of the cantonal hospital Baselland (grant number: N/A), the Basel Region Childhood Cancer Foundation (grant number: #2020-F009) and the “Berner Stiftung für krebskranke Kinder und Jugendliche” (grant number: N/A).

Data availability

Data privacy laws apply. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Competing interests

The authors declare no competing interests.

Ethics approval

The study involves human participants and was approved by ethics committee of Northwestern and Central Switzerland (EKNZ, 2017 − 00109).

Consent to participate

All participants provided informed consent prior to the study.